| B78 | Clinical characteristics and prognostic factors in people living with HIV hospitalized with COVID-19: findings from the WHO Global Clinical Platform | E-poster | COVID-19 morbidity and mortality in PLWH |
| B8 | Plasma separation cards are suitable for HIV-1 genotypic drug resistance testing | On-demand oral abstract session | Drug resistance testing |
| B8 | HIV-1 drug resistance mutations in proviruses of early treated infants in Botswana | E-poster | Drug resistance testing |
| B8 | Integrase genotyping is highly effective on diverse HIV-1 non-B clades circulating in Cameroon: toward a successful transition to dolutegravir-based regimens in Africa | E-poster | Drug resistance testing |
| B80 | Robust SARS-CoV-2-specific serological and functional t-cell immunity in PLWHIV | On-demand oral abstract session | Immune responses against SARS-CoV2 in PLWHIV |
| B9 | Is systematic Xpert MTB/RIF improved the detection of tuberculosis in HIV-infected patients in a low tuberculosis incidence setting in West Africa? | On-demand oral abstract session | Diagnosis of co-infections and co-morbidities |
| B9 | The point of care device needed for confirming active hepatitis C infection in the prison population | On-demand oral abstract session | Diagnosis of co-infections and co-morbidities |
| B9 | Combination of Xpert® MTB/RIF and DetermineTM TB LAM assay improves the diagnosis of extrapulmonary tuberculosis at Jimma University Medical Center, Southwest Ethiopia | E-poster | Diagnosis of co-infections and co-morbidities |
| B9 | Serum CA-125 in the diagnosis and therapeutic monitoring of tuberculosis in HIV infected patients | E-poster | Diagnosis of co-infections and co-morbidities |
| B9 | Values & preferences on hepatitis C self-testing among populations at increased risk of HCV, healthcare workers, and the general population: a multi-country rapid qualitative assessment | E-poster | Diagnosis of co-infections and co-morbidities |